Monte Rosa Therapeutics (GLUE) Competitors $7.67 -0.01 (-0.13%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends GLUE vs. HRMY, GLPG, XNCR, EVO, ARQT, RCUS, NRIX, IMCR, KNSA, and OCULShould you be buying Monte Rosa Therapeutics stock or one of its competitors? The main competitors of Monte Rosa Therapeutics include Harmony Biosciences (HRMY), Galapagos (GLPG), Xencor (XNCR), Evotec (EVO), Arcutis Biotherapeutics (ARQT), Arcus Biosciences (RCUS), Nurix Therapeutics (NRIX), Immunocore (IMCR), Kiniksa Pharmaceuticals (KNSA), and Ocular Therapeutix (OCUL). These companies are all part of the "pharmaceutical products" industry. Monte Rosa Therapeutics vs. Harmony Biosciences Galapagos Xencor Evotec Arcutis Biotherapeutics Arcus Biosciences Nurix Therapeutics Immunocore Kiniksa Pharmaceuticals Ocular Therapeutix Monte Rosa Therapeutics (NASDAQ:GLUE) and Harmony Biosciences (NASDAQ:HRMY) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, community ranking, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings. Which has stronger valuation and earnings, GLUE or HRMY? Harmony Biosciences has higher revenue and earnings than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMonte Rosa Therapeutics$14.98M31.47-$135.35M-$1.83-4.19Harmony Biosciences$681.88M2.81$128.85M$2.1115.94 Do analysts rate GLUE or HRMY? Monte Rosa Therapeutics presently has a consensus target price of $16.00, suggesting a potential upside of 108.60%. Harmony Biosciences has a consensus target price of $49.80, suggesting a potential upside of 48.08%. Given Monte Rosa Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Monte Rosa Therapeutics is more favorable than Harmony Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Monte Rosa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Harmony Biosciences 2 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.60 Does the media favor GLUE or HRMY? In the previous week, Harmony Biosciences had 2 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 6 mentions for Harmony Biosciences and 4 mentions for Monte Rosa Therapeutics. Harmony Biosciences' average media sentiment score of 0.59 beat Monte Rosa Therapeutics' score of 0.16 indicating that Harmony Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Harmony Biosciences 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, GLUE or HRMY? Monte Rosa Therapeutics has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500. Comparatively, Harmony Biosciences has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Does the MarketBeat Community believe in GLUE or HRMY? Harmony Biosciences received 40 more outperform votes than Monte Rosa Therapeutics when rated by MarketBeat users. Likewise, 66.67% of users gave Harmony Biosciences an outperform vote while only 48.28% of users gave Monte Rosa Therapeutics an outperform vote. CompanyUnderperformOutperformMonte Rosa TherapeuticsOutperform Votes1448.28% Underperform Votes1551.72% Harmony BiosciencesOutperform Votes5466.67% Underperform Votes2733.33% Is GLUE or HRMY more profitable? Harmony Biosciences has a net margin of 17.98% compared to Monte Rosa Therapeutics' net margin of 0.00%. Harmony Biosciences' return on equity of 23.16% beat Monte Rosa Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Monte Rosa TherapeuticsN/A -62.68% -38.83% Harmony Biosciences 17.98%23.16%14.24% Do insiders & institutionals have more ownership in GLUE or HRMY? 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are held by institutional investors. 6.5% of Monte Rosa Therapeutics shares are held by company insiders. Comparatively, 30.8% of Harmony Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryHarmony Biosciences beats Monte Rosa Therapeutics on 14 of the 18 factors compared between the two stocks. Ad Porter & CompanyMusk threatens Liberal’s fake “energy crisis”Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Get Monte Rosa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLUE vs. The Competition Export to ExcelMetricMonte Rosa TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$471.22M$2.98B$5.17B$9.30BDividend YieldN/A1.85%4.77%4.06%P/E Ratio-4.1946.02132.2217.52Price / Sales31.47409.351,256.58139.03Price / CashN/A182.1340.7837.95Price / Book2.143.924.904.91Net Income-$135.35M-$42.03M$118.85M$225.61M7 Day Performance-18.75%-4.04%14.53%-1.46%1 Month Performance-0.90%6.85%17.44%5.38%1 Year Performance53.40%20.53%35.31%22.72% Monte Rosa Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLUEMonte Rosa Therapeutics2.4508 of 5 stars$7.67-0.1%$16.00+108.6%+53.4%$471.22M$14.98M-4.1990HRMYHarmony Biosciences4.7533 of 5 stars$33.01+1.9%$47.00+42.4%-0.1%$1.88B$681.88M15.59200Analyst ForecastShort Interest ↓GLPGGalapagos0.74 of 5 stars$26.91+0.3%$30.75+14.3%-31.6%$1.77B$260.09M0.001,123XNCRXencor4.1914 of 5 stars$24.52+2.0%$36.56+49.1%+19.7%$1.72B$168.34M-7.51280EVOEvotec1.4771 of 5 stars$4.67+4.0%$5.93+27.1%-56.6%$1.65B$777.05M0.005,061Short Interest ↓ARQTArcutis Biotherapeutics0.9512 of 5 stars$13.57+6.9%$15.50+14.2%+509.0%$1.59B$138.71M-7.58150Options VolumeRCUSArcus Biosciences2.5772 of 5 stars$16.51+2.7%$34.00+105.9%-11.3%$1.51B$117M-5.11500NRIXNurix Therapeutics2.8215 of 5 stars$20.81+2.7%$30.35+45.9%+133.3%$1.47B$56.42M-6.97300IMCRImmunocore2.6344 of 5 stars$29.30+1.3%$65.64+124.0%-54.2%$1.47B$296.31M-30.43497Short Interest ↓KNSAKiniksa Pharmaceuticals2.6462 of 5 stars$20.30+0.5%$36.60+80.3%+13.9%$1.47B$384.10M-147.36220Positive NewsOCULOcular Therapeutix3.7845 of 5 stars$8.98+3.3%$16.71+86.1%+129.5%$1.37B$61.44M-6.80267Positive News Related Companies and Tools Related Companies HRMY Alternatives GLPG Alternatives XNCR Alternatives EVO Alternatives ARQT Alternatives RCUS Alternatives NRIX Alternatives IMCR Alternatives KNSA Alternatives OCUL Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GLUE) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monte Rosa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GLUE Stock Alerts